Biologics Fill Finish Manufacturing Market Size Worth over USD 8.4 Billion in 2035 | Roots Analysis

Various challenges associated with the fill finish process of biologics, such as ensuring sterility, assuring accurate fill volumes, limitations of analytical sciences, lack of incentives and the stringent statutory and regulatory framework, have contributed heavily to the demand for consistent evolution of product development and manufacturing processes.

Furthermore, it is often challenging for the drug developers to keep up with the latest manufacturing and fill finish trends and technologies. These aforementioned difficulties faced by drugs developers are likely to translate into lucrative business opportunities for biologics fill finish contract manufacturing organizations.

Key Report Takeaways

Currently, 240 service providers are engaged in offering fill finish services for different types of biologics; majority of these firms are headquartered in developed geographies

The current market landscape is highly fragmented, featuring the presence of both new entrants and established players; of these, over 60% of biologics fill / finish service providers were established post-2000

Vials have emerged as the most adopted primary packaging container format; further, close to 75% of the players offer services for filling both liquid and lyophilized form of biologic drugs

In pursuit of building a competitive edge, stakeholders are actively upgrading their existing fill finish capabilities and enhancing their respective service offerings to comply with the evolving industry benchmarks

The current global installed biologics fill / finish capacity is estimated to be more than 70 million units; majority of this capacity is installed in the facilities located in Europe

The current demand for biologics fill / finish manufacturing is estimated to be over 7.5 million liters; moreover, 35 top selling biologics contribute to 90% of overall revenues generated within the biopharmaceutical market

As a result of the growing demand for biologics in personalized healthcare, the biologics fill finish manufacturing market is likely to grow at a CAGR of close to 7.5% over the next 11 years

The market is expected to be well distributed across different type of primary packaging container, biologic manufactured, scale of operation, therapeutic area, end-users, and key geographical regions

Competitive Landscape:

The biologics fill finish manufacturing market landscape features 240 very large, large, mid-sized and small fill finish providers which claim to have the required expertise and technologies to offer fill finish and packaging services for different types of biologic drug products. It is worth highlighting that close to 95% of the service providers offer biologic filling services into vials.

Additionally, close to 60% of the biologics fill finish manufacturing companies are engaged in offering filling services for syringes. Notable examples of such companies include (in alphabetical order, headquartered in North America) August bioservices, Axcellerate Pharma, Lubrizol Life Science Health, PCI Pharma Services and Zencore Biologics.

Biologics Fill Finish Manufacturing Market Regional Outlook

Based on the key geographical regions, the market can be segmented into four major regions, North America, Europe, Asia Pacific and the rest of the world. Majority of the biologics fill finish service providers are headquartered in North America and Europe.

Currently, Europe captures around 40% of the market share of the global biologics fill finish manufacturing market and this trend is unlikely to change in the future. This can be attributed to the rising demand as well as regulatory support for approval of biologic drug products in the European region which has resulted in an increase in the number of installed fill finish facilities required to cater the commercial production of these large molecules.

Further, it is worth highlighting that, in the coming years, the market in Asia-Pacific is likely to grow at a higher rate owing to the lower manufacturing costs, cheap and skilled labor and supportive regulatory landscapes in this region.

Key Players

Examples of key companies engaged in biologics fill finish manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie Contract Manufacturing, Asymchem, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River, Element Materials Technology, Evonik, Fareva, Fresenius Kabi, GSK, Hetero, Lonza, Patheon pharma services, Pierre Fabre, Recipharm, Sandoz, Syngene, WACKER, WuXi Biologics.

It is interesting to note that in January 2024, AbbVie Contract Manufacturing invested USD 223 million in order to expand biologic manufacturing capabilities at its facility located in Singapore.

Further, in October 2023, Lonza expanded its fill finish manufacturing capabilities at its facility based in Stein, Switzerland. The firm will construct a dedicated aseptic filling line for commercial scale production of antibody drug conjugates. Such types of developments are expected to drive the demand for biologics fill finish manufacturing across the globe, resulting in substantial market growth during the forecast period.

To get market data, market insights, financial statements and a comprehensive analysis of the please contact sales@rootsanalysis.com

Market Segments

Based on the research, Roots Analysis has segmented the Biologics Fill Finish Manufacturing Market into Type of Primary Packaging Container, Type of Biologic Manufactured, Scale of Operation, Therapeutic Area, End-users, Type of Player, Company Size and Key Geography Regions.

by Type of Primary Packaging Container

Ampoules

Cartridges

Syringes

Vials

by Type of Biologic Manufactured

Antibodies

Cell Therapies

Gene Therapies

Oligonucleotides

Recombinant Proteins

Vaccines

Other Biologics

by Scale of Operation

Preclinical / Clinical Scale

Commercial Scale

by Therapeutic Area

Autoimmune Disorders

Cardiovascular Disorders

Infectious Diseases

Metabolic Disorders

Oncological Diseases

Other Disorders

by End-users

Pharmaceutical / Biopharmaceutical Companies

Contract Manufacturing Organizations / Others

by Type of Player

Industry Player

Non-Industry Player

by Company Size

Small

Mid-sized

Large

by Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com